covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | October 28, 2020 | News story | Research and Development  

The coronavirus news this week focuses on clinical trials testing potential vaccines, with the University of Oxford and AstraZeneca stating they will continue their trials after a volunteer had died while on the study, and this vaccine candidate has recently shown promising immune potential across a wide range of evaluated participants.

In other news, the World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir should consider all the available evidence before awarding marketing authorisation to treat COVID-19, and not just the FDA’s approval last week.

1. Eli Lilly refutes FDA quality concerns at New Jersey facility producing COVID-19 drugPublished on 21/10/20

Eli Lilly has rebutted reports of FDA quality assurance concerns at its manufacturing facility in Branchburg, New Jersey, where it is producing bamlanivimab, an experimental antibody therapy to treat COVID-19, a week after the company stopped recruiting for clinical trials of the drug.

2. Patient dies on AstraZeneca COVID-19 vaccine trial, but didn’t receive vaccine dosePublished on 22/10/20

The University of Oxford and AstraZeneca say they will continue their coronavirus vaccine clinical trials after a volunteer had died while on the study.

3. AstraZeneca’s COVID-19 vaccine generates immune response in both old and young participantsPublished on 26/10/20

AstraZeneca’s much-hyped COVID-19 vaccine candidate, AZD1222, currently in development in partnership with the University of Oxford, has shown promising immune potential across a wide range of evaluated participants.

4. WHO warns regulators to consider all available evidence before approving remdesivir for COVID-19Published on 26/10/20

The World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir should consider all the available evidence before awarding marketing authorisation to treat COVID-19, and not just the FDA’s approval last week.

5. UK set to be first country to expose healthy people to COVID-19 in studiesPublished on 21/10/20

The UK is set to be the first country to conduct challenge trials which will see healthy volunteers intentionally exposed to COVID-19.

Conor Kavanagh

Related Content

No items found

Latest content